Advances in the Diagnosis of HIV-Associated Tuberculosis by Gupta-Wright, A & Lawn, SD
Gupta-Wright, A; Lawn, SD (2015) Advances in the Diagnosis of
HIV-Associated Tuberculosis. EMJ Respi, 3 (1). pp. 60-70.
Downloaded from: http://researchonline.lshtm.ac.uk/2235966/
DOI:
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
 RESPIRATORY  •  May 2015   EMJ  EUROPEAN MEDICAL JOURNAL  RESPIRATORY  •  May 2015   EMJ  EUROPEAN MEDICAL JOURNAL 60 61
ADVANCES IN THE DIAGNOSIS OF  
HIV-ASSOCIATED TUBERCULOSIS 
Ankur Gupta-Wright,1 *Stephen D. Lawn1,2
1. Department of Clinical Research, Faculty of Infectious and Tropical Diseases,  
London School of Hygiene and Tropical Medicine, London, UK
2. The Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine,  
Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
*Correspondence to stephen.lawn@lshtm.ac.uk
Disclosure: The authors have declared no conflicts of interest.
Received: 18.02.15 Accepted: 24.03.15
Citation: EMJ Respir. 2015;3[1]:60-70.
ABSTRACT
HIV-associated tuberculosis (HIV-TB) remains a global public health challenge, with the major burden 
being borne by countries in low-resource settings. If World Health Organization targets to reduce TB 
deaths by 95% and new cases by 90% are to be met by 2035, major improvements in diagnostic strategies 
are among the most pressing needs. HIV coinfection presents particular challenges in the diagnosis of TB 
due, for example, to the relatively low mycobacterial burden in sputum specimens and rapid dissemination 
beyond the lungs. Low and middle-income countries still typically rely on traditional diagnostics such as 
chest radiology and sputum microscopy, which lack sufficient accuracy. Desired characteristics for an 
HIV-TB diagnostic test are well described and include the ability to test a wide variety of clinical samples, 
diagnose extra-pulmonary TB, have good accuracy to detect low mycobacterial burden disease, and be 
deployable at the peripheries of healthcare systems. Following a long period of under-investment in TB 
research, development of TB diagnostics has progressed rapidly over the past decade and the technology 
landscape looks much more promising. This article will summarise advances in diagnostics that are 
particularly relevant to HIV-TB. The Xpert® MTB/RIF and Determine™ TB LAM assays have the most evidence 
assessing their use in HIV-TB. In addition to nucleic-acid amplification tests and antigen detection we will 
review new diagnostic technologies. Finally, we discuss whether use of empirical TB treatment offsets 
the potential impact and reduces the need for new diagnostics.
Keywords: Tuberculosis, HIV, AIDS, Mycobacterium tuberculosis, diagnosis, Xpert MTB/RIF, nucleic acid 
amplification test, lipoarabinomannan, Determine TB LAM, antigen detection, urine.
INTRODUCTION
HIV-associated tuberculosis (HIV-TB) remains a 
major global public health challenge and is the 
leading cause of HIV-related mortality with 
approximately 1.1 million cases and 360,000 deaths 
in 2013.1 Although Sub-Saharan Africa accounts for 
the majority of the global caseload (85%), focussed 
epidemics also occur elsewhere, for example, 
among intravenous drug users and prisoners in 
Eastern Europe, where there is a major overlap with 
high rates of drug-resistant TB and high mortality 
attributable to TB.1–4 In patients living with HIV 
infection, the relatively low mycobacterial burden 
in sputum specimens and rapid dissemination 
beyond the lungs render diagnosis challenging.5–9 
Low and middle-income countries still typically 
rely on traditional diagnostic tests such as chest 
radiology and sputum microscopy, which lack 
sufficient accuracy.10,11 Turnaround times for liquid 
culture (the most sensitive diagnostic test) are often 
too long to be clinically useful and the required 
laboratory infrastructure is very often not available 
in the highest-burden settings. Clinical suspicion 
and empirical treatment are widely used but can 
lead to under or over-treatment.12,13 Data from 
hospital post-mortem studies show that up to 
half of HIV-TB remains undiagnosed at the time 
of death.14–16
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Addressing the scale of the TB epidemic and 
accelerating progress towards elimination is the 
focus of an ambitious post-2015 Global Health 
Strategy announced by the World Health 
Organization (WHO) and partners.17 If targets to 
reduce TB deaths by 95% and new cases by 90% 
by 2035 are to be met, major improvements in 
diagnostic strategies are among the most pressing 
needs.17–19 WHO have also recognised the public 
health importance of HIV-TB coinfection and 
have recommended a series of 12 collaborative 
interventions to reduce the burden of HIV-TB and 
strengthen delivery of care;20 better diagnostics 
are central to many of these interventions.
Desired characteristics for an HIV-TB diagnostic 
test are well described,21 and include the ability 
to test a wide variety of clinical samples to 
detect extra-pulmonary TB (EPTB) in addition to 
pulmonary TB (PTB). Diagnostics need to be 
suitable for use at peripheral health units to screen 
those most at risk and intervene early in the 
disease. Point-of-care (PoC) assays are needed 
to enable diagnosis and treatment initiation in the 
same clinical encounter. Assays need to be 
amenable for use not only in adults but also 
in children, who are even less likely to be able 
to produce sputum and to test positive using 
smear microscopy.22 Diagnostic tests also need 
to differentiate latent from active TB (due to 
differences in their subsequent management) but 
still be able to detect low mycobacterial burden 
disease. Obtaining and testing samples should 
be safe for patients and healthcare workers, 
even in resource-limited settings where biosafety 
equipment is often unavailable. Multi-drug resistant 
TB (MDR-TB), which is a leading challenge for 
TB control and for which HIV is a risk factor,23,24 
remains mostly undiagnosed and inadequately 
treated due to lack of access to drug-susceptibility 
testing. Therefore, new diagnostics should 
ideally be able to screen simultaneously for drug 
resistance using the initial diagnostic sample. 
Following a long period of under-investment in TB 
research, development of laboratory diagnostics 
has progressed rapidly over the past decade and 
the technology landscape looks more promising 
(Figure 1). Advances include improvements in 
old diagnostic technologies such as sputum-
smear microscopy and culture-based systems.25,26 
However, much progress has also been made with 
respect to development of new technologies, 
including rapid molecular tests.27 This article will 
summarise advances in laboratory diagnostics 
that are particularly relevant to HIV-TB, focussing 
especially on recently developed technologies, 
but excluding radiological imaging techniques 
and advances in mycobacterial culture-based 
diagnostics. The enormous diagnostic challenges 
of TB drug resistance and TB diagnosis in HIV-
infected children are important, but are beyond 
the scope of the present article. Since the vast 
majority of the HIV-TB burden is in resource-limited 
settings where TB diagnostic capacity is weakest, 
we provide considerable focus on solutions for 
these settings. Finally, we discuss whether use of 
empirical TB treatment offsets the potential impact 
and reduces the need for new diagnostics.
NUCLEIC ACID AMPLIFICATION TESTS
Nucleic acid amplification tests (NAATs) rely 
on the amplification and detection of nucleic 
acid sequences specific to Mycobacterium 
tuberculosis (MTB) complex. Early NAATs were 
developed for TB over 20 years ago, although 
limited test performance meant that these were 
not widely implemented. Development of newer 
NAATs, however, makes them one of the leading 
commercially available TB diagnostic technologies 
at present (Figure 1). 
Line Probe Assays
Line probe assays (LPAs) use polymerase chain 
reaction (PCR) amplification of DNA for diagnosis 
directly from clinical samples or by testing culture 
isolates. Their use was endorsed by WHO in 
2008, and they are capable of screening for 
genotypic drug resistance by detecting known 
genetic mutations.29 A key disadvantage of LPAs 
is that they function best when testing samples 
with high bacillary load (smear-positive). The cost 
and complexity of LPAs also requires laboratory 
infrastructure and personnel capable of performing 
DNA extraction and PCR (rarely available in 
high-burden settings). Further advances in LPA 
technology now permit genotypic testing 
for resistance to some second-line TB drugs 
with moderate sensitivity and high specificity 
(GenoType MTBDRsl assay, Hain Lifescience, 
Germany).30 Moreover, newer assays have lower 
limits of detection and can be used to directly 
test smear-negative sputum samples (MTBDRplus 
version 2.0, Hain Lifescience).31–33 These have the 
potential to be used at reference laboratory level 
and screen for resistance to important second-line 
agents, especially in better-resourced settings and 
where drug resistance is more common.
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Xpert MTB/RIF Assay
The next NAAT endorsed by WHO has been 
referred to as a ‘game changer’ in the field of TB 
diagnostics. The Xpert MTB/RIF assay (Xpert, 
Cepheid Inc., USA) is a self-contained, fully 
integrated, and semi-automated NAAT developed 
for relatively unskilled users.34,35 Within a single-
use cartridge, it uses hemi-nested real-time PCR 
and ‘molecular beacon’ technology to detect 
DNA sequences within MTB’s RNA polymerase β 
subunit gene (rpoB), allowing diagnosis of MTB 
and genotypic detection of 95% of rifampicin 
(RIF)-resistant strains.36–38 It was endorsed by the 
WHO in 2010 due to its diagnostic accuracy and 
several other positive attributes.39 These included 
ease of use, a substantially reduced biosafety risk 
Figure 1: Current tuberculosis diagnostics pipeline listing examples of different types of diagnostics 
and their development phase (as of October 2014). 
WHO: World Health Organization; LED: light-emitting diode; MODS: microscopic observation of 
drug susceptibility; LAM: lipoarabinomannan; MTB/RIF: mycobacterium tuberculosis/rifampicin; 
TB: tuberculosis. 
Adapted from FIND, UNITAID,27 and Geneva.117
Endorsed by WHODue to be evaluated by WHO soonLate developmentEarly development
MOLECULAR TECHNOLOGIES
• Xpert XDR (Cepheid, 
USA)
• Alere Q (Alere, USA)
• TruArray MDR-TB  
(Akkoni, USA)
• INFINITIMTB  
(Autogenomics, USA)
• iCubate 2.0 (iCubate, 
USA)
• Genedrive MTB/RIF ID 
(Epistem, UK)
• Truelab/Truenat MTB 
(Molbio/Bigtec  
Diagnostics, India)
• TB drug resistance  
assay (Capital Bio, 
China)
• TB LAMP (Eiken,  
Japan)
• GenoTYPE MTBDRsl 
(Hain Lifesciences, 
Germany)
• Xpert MTB/RIF  
(pulmonary,  
extra-pulmonary and  
paediatric, Cepheid, 
USA)
• Line probe assays for 
MTB and rifampicin 
resistance detection on 
smear +ve or culture 
+ve samples
NON-MOLECULAR TECHNOLOGIES
Culture-based  
technologies
• BNP Middlebrook  
(NanoLogix, USA)
• Rapid colourimetric 
DST
• Volatile organic  
compounds
• Breathlink (Menssana, 
USA)
• Prototype  
breathalyzer device 
(Next Dimensions, 
USA)
Other
• Multiplex antibody  
array (mBio, USA)
• LAM in sputum  
(Standard Diagnostics, 
South Korea)
Microscopy
• Microimager (BD, USA)
Culture-based  
technologies
• TREK sensititre  
MYCOTB MIC plate 
(Trek, USA)
Volatile organic  
compounds
• Giant African pouch 
rats (APOPO, Belgium)
Other
• CAD4TB (Delft  
Imaging Systems,  
Netherlands)
Antigen-based  
technology
• Alere Determine  
TB LAM (Alere, USA)
Microscopy
• Light and LED  
microscopy
• Same-day diagnosis
Culture-based  
technology
• Non-commercial  
culture (e.g. MODS)
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compared with sputum-smear microscopy, and 
relatively short processing time (just over 2 h).40,41 
Initial recommendations were for Xpert’s use as 
the primary diagnostic test for HIV-TB, or in 
settings where MDR-TB was suspected.41
The potential limitations of Xpert use in resource-
constrained settings include the need for a stable 
electricity supply and operating temperatures, 
external quality assurance, regular calibration of 
instruments, and robust supply chains and storage 
facilities for Xpert cartridges.42 On a health-systems 
level, challenges to implementation and scale-up 
include changes to diagnostic pathways, policies 
and notification systems, increased human resource 
needs, and increased capacity for investigating 
and treating suspected drug-resistant TB.42 These 
logistical and health-system factors may mean that 
use of Xpert outside of the laboratory environment 
will be challenging, which may in turn reduce 
potential impacts of Xpert on patient outcomes.43
Several studies assessing the diagnostic accuracy 
of the Xpert for HIV-TB have been undertaken 
since the seminal multi-country assessment.44 The 
pooled sensitivity of Xpert for diagnosis of PTB in 
HIV-infected individuals is 79% (95% confidence 
interval [CI]: 70-86%), and specificity is 99% (95% 
CI: 98-100%).32 Sensitivity is 61% (95% CI: 40-81%) 
for sputum smear-negative TB, compared with 
97% (95% CI: 90-99%) for sputum smear-positive 
disease.32 Xpert’s sensitivity is related to 
mycobacterial load, thus it is likely to be lower 
in patient populations with fewer symptoms and 
low rates of smear-positive disease, for example, 
screening asymptomatic HIV-infected patients.42,45 
This may explain the variability in sensitivity 
observed between studies.
Xpert MTB/RIF assay for non-respiratory samples
The high proportion of patients with HIV-TB who 
have EPTB provides another important diagnostic 
opportunity using this assay.46 Systematic reviews 
have reported very high specificity of Xpert when 
testing a very wide variety of non-respiratory 
clinical samples,47,48 despite the fact that culture is 
an imperfect reference standard for EPTB and may 
lead to underestimation of specificity.49 
Overall sensitivity was high for smear-positive 
samples (97.4%, 95% CI: 95.5-99.3%)47 and for all 
culture-positive samples tested (median: 83%, 
interquartile range [IQR]: 68-94%).48 Sensitivity 
using a culture reference standard varied 
substantially between sample types, with good 
sensitivity observed in lymph node tissue (83.1%, 
95% CI: 71.4-90.7%) and cerebrospinal fluid (80.5%, 
95% CI: 59.0-92.2%), and poor sensitivity in pleural 
fluid (46.4%, 95% CI: 26.3-67.8%).47 It is difficult to 
directly compare the diagnostic accuracy of Xpert 
for EPTB in HIV-infected and uninfected individuals 
due to paucity of data, but accuracy estimates 
did not differ substantially in studies with 
high proportions of HIV-infected patients.47 
WHO has now endorsed the use of Xpert for 
non-respiratory samples.50
Two studies have also assessed the Xpert’s utility 
in diagnosing HIV-TB using urine samples. Urine 
was positive in 44.4% of outpatients with sputum 
culture-positive TB and CD4 count <50 cells/µl, 
and 47.8% of inpatients with culture-positive 
HIV-TB.51,52 Diagnostic yield was higher among 
those with lower CD4 counts (<100 cells/µl) in 
both studies, suggesting positive urine samples 
represent disseminated TB in the sickest 
HIV-infected patients. 
Xpert MTB/RIF assay in resource-rich settings
Few data exist on the use of Xpert in resource-rich 
settings, despite recommendations in guidelines 
and wide availability in European centres.53,54 A 
study conducted in a university hospital TB clinic 
in Canada (low TB and HIV prevalence) reported 
only moderate sensitivity compared with liquid-
culture reference standard (46% overall, 28% in 
smear-negative cases).55 It was concluded that 
the potential for impact was minimal due to less 
extensive TB disease on admission and robust 
existing diagnostic algorithms. However, other 
researchers have suggested that using Xpert as 
the initial investigation for TB could reduce the 
use of empirical treatment, unnecessary contact 
investigations, in-hospital respiratory isolation, and 
length of hospital stay.56–58 There is also potential 
impact when used as a ‘rule-in’ test,59 for example 
in immunosuppressed HIV-infected patients, when 
TB is a common opportunistic infection and can 
be difficult to rapidly distinguish from non-
tuberculous mycobacterial (NTM) disease and other 
bacterial infections. There is also potential benefit 
in settings where HIV-TB and MDR-TB overlap 
(for example prison populations and injecting 
drug users), as Xpert has demonstrated accurate 
detection of MTB and RIF resistance.60 However, 
cost-effectiveness of the Xpert assay has not 
been proven in resource-rich settings, and this will 
depend on factors such as prevalence of HIV, 
MDR-TB, and existing laboratory infrastructure.61
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Loop-Mediated Isothermal Amplification
The loop-mediated isothermal amplification (LAMP, 
Eiken Chemical Co, Japan) is another simplified 
laboratory-based NAAT that is under development 
for use in resource-limited settings. Up to 14 
specimens can be batch-processed in 2 hours, and 
the assay detects MTB by rapidly amplifying DNA 
in sufficient quantities so that results can be read 
by simple visual determination of fluorescence 
(compared with positive and negative controls).27,62 
Although no specific large-scale evaluations 
have been undertaken for HIV-TB, sensitivity and 
specificity for PTB were 80% (95% CI: 86-93%) and 
96% (95% CI: 95-97%), respectively, compared with 
culture reference standard.63 Sensitivity is lower 
when testing smear-negative samples (53.8%), 
suggesting that it may be less useful in the context 
of HIV.64 WHO endorsement was declined in 2013 
due to ‘inadequate evidence’ and persisting concerns 
over sub-optimal specificity.65 However, further 
evaluations are underway.
Emerging Nucleic Acid Amplification  
Test Technologies
Several ‘fast follower’ technologies to Xpert are 
emerging, although none have yet been endorsed 
by WHO (Figure 1).27 These systems have several 
potential benefits over the Xpert. Many are smaller 
(often handheld), more robust, lower-cost, have 
lower power requirements due to isothermal 
amplification, and can operate from batteries. 
Genedrive (Epistem, United Kingdom) is a new 
molecular PoC PCR that can diagnose MTB and 
detect genotypic RIF resistance.27 A single study 
reported sensitivity of 90.8% (95% CI: 81.0-
96.5%) for MTB and 72.3% (95% CI: 59.8-82.7%) 
for rpoB mutations, although few smear-negative 
samples were assessed.66 Truelab MTB (Mobilio, 
India) is a chip-based NAAT using a battery-
powered device with sensitivity of 99.1% in smear- 
positive pulmonary TB, and 75.9% in smear- 
negative, culture-positive pulmonary TB, with 
100% specificity.27,67 If these PoC technologies 
demonstrate good sensitivity for specimens 
with low mycobacterial load then there is huge 
potential for their use in screening HIV-infected 
patients for TB, and large studies in high-burden 
settings will be warranted.
ANTIGEN DETECTION
Whereas immune-based assays of the host 
response to MTB are likely to be undermined in 
patients with HIV coinfection, direct detection of 
MTB antigens has long been recognised as having 
great diagnostic potential in such patients. Several 
different antigens have been detected in the 
urine of patients with pulmonary TB.68,69 Urine has 
several advantages over sputum as a diagnostic 
medium, including relative ease of collection 
and lower biohazard risk during specimen 
handling. The most promising antigen to date is 
lipoarabinomannan (LAM), a major glycolipid 
component of the MTB cell wall, and commercial 
enzyme-linked immunosorbent assays detecting 
LAM have been available for a decade.70,71 LAM is 
released from metabolically active MTB and is only 
detectable in those with active TB as opposed to 
latent infection. The mechanism by which LAM 
enters the urine of TB patients remains unproven, 
but possible mechanisms are free LAM entering 
the urine from the systemic circulation or direct 
infection of the renal tract with MTB.72,73
Urine Lipoarabinomannan Assays
Over the past 3 years, a simple and low-cost lateral-
flow assay has become commercially available 
(Determine TB LAM Ag, Alere, USA). This test can 
be performed at the bedside by adding 60 µl of 
unprocessed urine to the test strip - the result is 
read after 25 minutes by comparing visible bands 
with the manufacturer’s reference card (Figure 2). 
In contrast to other diagnostic assays for TB, 
urine-based LAM detection appears to have 
greater diagnostic accuracy in patients with HIV 
coinfection.74 Sensitivity is <25% in HIV-uninfected 
populations, making it of little diagnostic use in 
this group.74
Several studies have assessed the diagnostic 
accuracy of urine-LAM testing for HIV-TB. Early 
studies reported a pooled sensitivity of 56% 
(95% CI: 40-71%) and specificity of 95% (95% CI: 
77-99%).74 A key observation is that diagnostic 
accuracy increases with more advanced degrees 
of immunosuppression.72,75 This probably relates to 
higher mycobacterial load and more disseminated 
disease leading to greater probability of renal 
involvement.15,76–78 Studies stratifying urine LAM 
by CD4 cell count have shown sensitivities of 56-
85% among patients with CD4 <50 cells/µl.79–85 
Similarly, sensitivity has been found to be higher 
among hospital inpatients than among outpatients 
(58-67% versus 17-32%),79–81,84–86 reflecting the 
strong relationship between higher sensitivity and 
greater disease severity.87
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Some variation in specificity of urine-LAM assays 
has been reported between studies. Most report 
excellent specificity (96-100%), but some report 
lower specificities (86-89%).75 The most likely 
reasons are: (i) inadequate reference standard 
using only sputum culture underestimates true 
prevalence of HIV-TB due to difficulty obtaining 
quality sputum samples and missing HIV-TB without 
pulmonary involvement;88 (ii) using the ‘Grade-1’ 
cutoff for the TB LAM assay - a very faint band on 
the test strip that is difficult to read accurately.75 
Using ‘Grade-2’ rather than ‘Grade-1’ cutoffs for TB 
LAM improves specificity with only small decreases 
in sensitivity.78,81 Consensus among investigators 
is that only ‘Grade-2’ cutoffs should be used,89 
and since January 2014 the manufacturer of TB 
LAM has removed the old ‘Grade-1’ cutoff from 
reference cards.80 Disease due to NTM90 or urine 
contamination with NTM could also theoretically 
cause false-positive results. The use of the urine 
LAM lateral-flow assay will be subject to a WHO 
expert review in 2015.
Urine Sampling May Increase Overall 
Diagnostic Yield 
Urine-LAM testing identifies a different population 
of HIV-TB patients compared with sputum-
based diagnostic assays, raising the possibility 
of combining them to screen for or diagnose 
HIV-TB. Studies using both urine and sputum-
based diagnostics have demonstrated increased 
diagnostic yield compared to sputum alone, 
identifying up to 70-90% of diagnosable TB 
(Figure 3).76,81,82,91 Similarly, urine LAM identified a 
different population to those treated empirically for 
HIV-TB.52 In addition to increasing diagnostic yield, 
urine LAM appears to identify those patients who 
have higher mortality risk.92,93 It is these patients 
who are most likely to benefit from interventions 
such as early commencement of TB treatment. 
By virtue of its low cost (approximately US$3.50 
per test), technically simple operation, and rapid 
results, TB LAM appears to be well suited for use 
in low-resource settings with high HIV-TB burden. 
Figure 2: Photograph of a Determine TB LAM test strip showing the sample pad to which 60 µl of the 
test urine is applied, patient sample result, control band, and manufacturer’s reference card.
TB: tuberculosis; LAM: lipoarabinomannan.
Reproduced from Lawn75 with authors’ permission.
Control band
Patient sample result
Sample pad
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Given its modest sensitivity and potential overlap 
with NTM, its role in resource-rich settings is less 
clear, although it could be utilised as a ‘rule-in’ test 
to expedite TB treatment when NAATs have failed 
and cultures and speciation are pending.94 
OTHER FUTURE 
DIAGNOSTIC TECHNOLOGIES
Several evolving technologies offer potential 
benefits for HIV-TB. Serological assays have a long 
history and have transformed the diagnosis of HIV 
and other infectious diseases. Current TB serological 
assays have limited accuracy and WHO has issued 
strong guidance against their use.95 However, this 
remains an important area for further research and 
development since improved serodiagnostics offer 
huge potential to be developed as PoC tests, which 
could diagnose EPTB (useful for HIV-TB).95,96 HIV-
TB presents particular challenges for serological 
assays, for example the heterogeneity of 
immunological responses to MTB.97,98
A recent case–control study examined antibody 
responses to several MTB proteins in HIV-TB and 
demonstrated moderate sensitivity.99 Serological 
positivity was also common in HIV-infected 
controls, but the cross-sectional design was 
unable to differentiate poor specificity from early, 
subclinical disease that may have progressed to 
active TB.99 It appears that a pooled group of 
antigens gives a superior performance, and 
multiplex PoC diagnostics are being developed 
which can assess up to 57 MTB antigens with 
150 µl of whole blood added directly to a 
cartridge.27 MTB’s production of specific volatile 
organic compounds has the potential to be used 
in PoC tests to discriminate patients with active 
TB infection.27,100 Other ‘breath tests’ have already 
shown that they can discriminate isoniazid-
susceptible MTB, isoniazid-resistant MTB, and 
other common lung pathogens.101
DOES EMPIRICAL TUBERCULOSIS
TREATMENT NEGATE THE NEED FOR
NEW TUBERCULOSIS DIAGNOSTICS?
There was much enthusiasm following the 
promising results of early assessments of the 
Xpert MTB/RIF assay and WHO endorsement. 
Subsequent substantial investment by donors 
and governments has led to rapid global 
implementation.102 Several studies have modelled 
a positive impact of scaling-up of Xpert on 
economic, individual, and population-level 
outcomes.103–107 However, whilst data from high HIV-
Figure 3: Graph showing relative diagnostic yields (and 95% confidence intervals) of a sputum-based 
diagnostic (Xpert MTB/RIF assay) and urine-based diagnostic (Xpert MTB/RIF or Determine TB LAM 
assays), both compared with HIV-associated tuberculosis diagnosed by any microbiological test. 
MTB/RIF: mycobacterium tuberculosis/rifampicin; TB: tuberculosis; LAM: lipoarabinomannan.
Data from Lawn et al.76
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burden settings have demonstrated that Xpert has 
superior diagnostic accuracy to sputum-smear 
microscopy and can improve time to diagnosis, 
any impact on morbidity or mortality is yet to 
be demonstrated.108–112
One major hypothesis for this failure to observe a 
beneficial impact is the use of ‘empirical’ treatment 
for TB clinically diagnosed by clinicians in the 
absence of positive TB diagnostics, especially in the 
context of HIV coinfection.113 Empirical TB treatment 
(defined as the decision to commence TB treatment 
in the absence of bacteriologically confirmed TB 
using smear microscopy, culture, or WHO-endorsed 
rapid diagnostics114) remains poorly studied but 
is likely to be done in a non-standardised fashion 
and be influenced by several factors, including 
poor sensitivity of traditional TB diagnostics, high 
TB prevalence (a high pre-test probability), high 
mortality in HIV-TB (therefore little to lose by 
treating TB), cadre of healthcare worker, and 
availability of adjunctive therapies. A meta-analysis 
of the WHO algorithm13 for smear-negative TB in 
high HIV-prevalent settings estimated pooled 
sensitivity of 61% (95% CI: 55-67%) and specificity 
was 69% (95% CI: 66-72%).115 It is difficult to 
standardise empirical treatment, and therefore 
difficult to estimate accuracy and account for it 
in models.
The TB-NEAT study110 noted that of the smear-
negative patients detected by Xpert, 93% were 
treated empirically by clinicians. A legitimate 
concern is that Xpert may simply be confirming 
a TB diagnosis in those who would receive TB 
treatment anyway, negating the potential benefit 
of Xpert (or other new diagnostics) on individual 
and population-level outcomes.113 Models 
attempting to adjust for empirical therapy have 
also reflected this.116 However, empirical TB 
treatment also has potential harms through 
overtreatment, including cost to patients and 
healthcare systems, unnecessary drug toxicities 
which are more common in the context 
of concomitant antiretroviral therapy, and 
inappropriate treatment of unsuspected MDR-
TB. Post-mortem studies also demonstrate that 
empirical treatment misses large numbers of HIV-
TB cases.14–16 Further studies from a wide variety 
of settings are required to understand empirical 
TB treatment, in particular the impact of new 
diagnostics such as Xpert. However, there is a real 
danger that certain features of the design and 
conduct of TB diagnostics intervention trials may 
actually increase the likelihood of empirical TB 
treatment being prescribed.117 Thus, future trial 
designs for new diagnostics must account for 
empirical treatment, as should studies modelling 
implementation and scale-up.
CONCLUSION
In conclusion, HIV-TB remains a major public health 
burden. Improved diagnostics are considered 
crucial to addressing this public health challenge, 
especially in resource-limited settings. At present 
the most progressive technologies are the Xpert 
MTB/RIF assay and urine TB LAM assays, although 
clinical impact at an individual or population 
level has yet to be demonstrated. After decades 
of neglect the TB diagnostics pipeline looks 
promising, with several new diagnostic technologies 
that could be applicable to the challenges of HIV-
TB. However, future diagnostics need evidence of 
impact beyond simple diagnostic accuracy before 
scale-up and widespread implementation. This 
includes clinical trials assessing clinical outcomes 
in a variety of settings and must take into account 
the use of empirical treatment. 
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